Hormonal-Receptors-Positive and HER2-Negative Patients with Metastatic Breast Cancer Treated with First-Line Palbociclib and Hormonal Therapy: Impact of First-Cycle Neutropenia and Dose Reduction on Therapeutic Outcome

Table 1

Baseline clinicopathological factors and relation to neutropenia after 1^st cycle.

Parameters		Neutropenia		Total	P value
		No	Yes
ECOG PS	0	0	2	2	0.82
		0.0%	100.0%	100.0%
	1	15	94	109
		13.8%	86.2%	100.0%
	2	6	33	39
		15.4%	84.6%	100.0%
BMI	Normal	2	21	23	0.71
		8.7%	91.3%	100.0%
	Overweight	7	37	44
		15.9%	84.1%	100.0%
	Obese	12	71	83
		14.5%	85.5%	100.0%
Ki67 level	Low	15	71	86	0.02
		17.4%	82.6%	100.0%
	High	4	56	60
		6.7%	93.3%	100.0%
	NA	2	2	4
		50.0%	50.0%	100.0%
Menopausal status	Premenopause	8	70	78	0.17
		10.3%	89.7%	100.0%
	Postmenopause	13	59	72
		18.1%	81.9%	100.0%
Low HER2 expression	No	10	73	83	0.44
		12.0%	88.0%	100.0%
	Yes	11	56	67
		16.4%	83.6%	100.0%
Stage at diagnosis	Stage II	1	3	4	0.68
		25.0%	75.0%	100.0%
	Stage III	8	42	50
		16.0%	84.0%	100.0%
	Stage IV	12	84	96
		12.5%	87.5%	100.0%
N-stage	Nx	3	1	4	0.008
		75.0%	25.0%	100.0%
	N0	20	70	90
		22.2%	77.8%	100.0%
	N1	5	59	64
		7.8%	92.2%	100.0%
	N2	4	30	34
		11.8%	88.2%	100.0%
	N3	2	9	11
		18.2%	81.8%	100.0%
(Neo) adjuvant chemotherapy	No	17	111	128	0.48
		13.3%	86.7%	100.0%
	Yes	4	17	21
		19.0%	81.0%	100.0%
PR-status	Negative	4	19	23	0.61
		17.4%	82.6%	100.0%
	Positive	17	110	127
		13.4%	86.6%	100.0%
Site of metastasis	Bone-only	5	27	32	0.76
		15.6%	84.4%	100.0%
	Others	16	102	118
		13.6%	86.4%	100.0%
Site of metastasis	Single	8	46	54	0.83
		14.8%	85.2%	100.0%
	Multiple	13	83	96
		13.5%	86.5%	100.0%